Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxaneMarcin Kubeczko, Fara Brasó-Maristany, Rodrigo Sánchez-Bayona et al.|npj Breast Cancer|2026Cited by 0